COAG
Hemab Therapeutics Holdings, Inc.
39.33
+0.56 (+1.44%)
52w low 23.00
55.42 high
50.4% of range
Financial Analysis
| (USD) | Mar 25 | Jun 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 16.56M | 16.06M | 23.61M | 26.08M | |
| R&D | 14.10M | 12.87M | 19.46M | 20.34M | |
| SG&A | 2.46M | 3.18M | 4.15M | 5.74M | |
| Operating Income | -16.56M | -16.06M | -23.61M | -26.08M | |
| EBITDA | -16.48M | -15.98M | -23.54M | -26.00M | |
| Pretax Income | -15.50M | -12.21M | -22.68M | -24.05M | |
| Income Tax | -190.00K | 4.00K | 12.00K | 97.00K | |
| Net Income | -15.31M | -12.21M | -22.69M | -24.15M | |
| EPS Diluted | -0.56 | -0.44 | -0.51 | -0.80 | |
| Diluted Shares | 27.44M | 27.44M | 44.19M | 30.11M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--